AllergoOncology: Microbiota in allergy and cancer: a European Academy for Allergy and Clinical Immunology position paper

Eva Untersmayr; Heather J. Bax; Christoph Bergmann; Rodolfo Bianchini; Wendy Cozen; Hannah J. Gould; Karin Hartmann; Debra H. Josephs; Francesca Levi-Schaffer; Manuel L. Penichet; Liam O'Mahony; Aurelie Poli; Frank A. Redegeld; Franziska Roth-Walter; Michelle C. Turner; Luca Vangelista; Sophia N. Karagiannis; Erika Jensen-Jarolim

doi:10.1111/all.13718

AllergoOncology: Microbiota in allergy and cancer: a European Academy for Allergy and Clinical Immunology position paper

Eva Untersmayr, Heather J. Bax, Christoph Bergmann, Rodolfo Bianchini, Wendy Cozen, Hannah J. Gould, Karin Hartmann, Debra H. Josephs, Francesca Levi-Schaffer, Manuel L. Penichet, Liam O'Mahony, Aurelie Poli, Frank A. Redegeld, Franziska Roth-Walter, Michelle C. Turner, Luca Vangelista, Sophia N. Karagiannis^*, Erika Jensen-Jarolim

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

308 Downloads (Pure)

Abstract

The microbiota can play important roles in the development of human immunity and the establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer medications, regulate phylogenetic variability and the quality of cross talk between innate and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and their composition have been linked to protective effects for health. Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, characterized by impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position paper, we focus on the increasing evidence defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the risk for the development of allergic and malignant diseases. We discuss novel insights into the role of microbiota in disease and patient responses to treatments in cancer and in allergy. These may highlight opportunities to improve patient outcomes with medical interventions supported through a restored microbiome.

Original language	English
Pages (from-to)	1037-1051
Number of pages	15
Journal	Allergy
Volume	74
Issue number	6
DOIs	https://doi.org/10.1111/all.13718
Publication status	Published - 1 Jun 2019

Keywords

allergy
cancer
hygiene hypothesis
microbiota
oncoimmunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/all.13718Licence: CC BY

AllergoOncology_UNTERSMAYR_Publishedonline12January2019_GREEN AAMAccepted author manuscript, 562 KB
Untersmayr_et_al-2019-AllergyAccepted author manuscript, 562 KB

Cite this

Untersmayr, E., Bax, H. J., Bergmann, C., Bianchini, R., Cozen, W., Gould, H. J., Hartmann, K., Josephs, D. H., Levi-Schaffer, F., Penichet, M. L., O'Mahony, L., Poli, A., Redegeld, F. A., Roth-Walter, F., Turner, M. C., Vangelista, L., Karagiannis, S. N., & Jensen-Jarolim, E. (2019). AllergoOncology: Microbiota in allergy and cancer: a European Academy for Allergy and Clinical Immunology position paper. Allergy, 74(6), 1037-1051. https://doi.org/10.1111/all.13718

@article{2709dcf4c6fc4d11a96a4dea3c657f60,

title = "AllergoOncology: Microbiota in allergy and cancer: a European Academy for Allergy and Clinical Immunology position paper",

abstract = "The microbiota can play important roles in the development of human immunity and the establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer medications, regulate phylogenetic variability and the quality of cross talk between innate and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and their composition have been linked to protective effects for health. Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, characterized by impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position paper, we focus on the increasing evidence defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the risk for the development of allergic and malignant diseases. We discuss novel insights into the role of microbiota in disease and patient responses to treatments in cancer and in allergy. These may highlight opportunities to improve patient outcomes with medical interventions supported through a restored microbiome.",

keywords = "allergy, cancer, hygiene hypothesis, microbiota, oncoimmunology",

author = "Eva Untersmayr and Bax, {Heather J.} and Christoph Bergmann and Rodolfo Bianchini and Wendy Cozen and Gould, {Hannah J.} and Karin Hartmann and Josephs, {Debra H.} and Francesca Levi-Schaffer and Penichet, {Manuel L.} and Liam O'Mahony and Aurelie Poli and Redegeld, {Frank A.} and Franziska Roth-Walter and Turner, {Michelle C.} and Luca Vangelista and Karagiannis, {Sophia N.} and Erika Jensen-Jarolim",

year = "2019",

month = jun,

day = "1",

doi = "10.1111/all.13718",

language = "English",

volume = "74",

pages = "1037--1051",

journal = "Allergy",

issn = "0105-4538",

publisher = "Blackwell Publishing",

number = "6",

}

Untersmayr, E, Bax, HJ, Bergmann, C, Bianchini, R, Cozen, W, Gould, HJ, Hartmann, K, Josephs, DH, Levi-Schaffer, F, Penichet, ML, O'Mahony, L, Poli, A, Redegeld, FA, Roth-Walter, F, Turner, MC, Vangelista, L, Karagiannis, SN & Jensen-Jarolim, E 2019, 'AllergoOncology: Microbiota in allergy and cancer: a European Academy for Allergy and Clinical Immunology position paper', Allergy, vol. 74, no. 6, pp. 1037-1051. https://doi.org/10.1111/all.13718

TY - JOUR

T1 - AllergoOncology: Microbiota in allergy and cancer

T2 - a European Academy for Allergy and Clinical Immunology position paper

AU - Untersmayr, Eva

AU - Bax, Heather J.

AU - Bergmann, Christoph

AU - Bianchini, Rodolfo

AU - Cozen, Wendy

AU - Gould, Hannah J.

AU - Hartmann, Karin

AU - Josephs, Debra H.

AU - Levi-Schaffer, Francesca

AU - Penichet, Manuel L.

AU - O'Mahony, Liam

AU - Poli, Aurelie

AU - Redegeld, Frank A.

AU - Roth-Walter, Franziska

AU - Turner, Michelle C.

AU - Vangelista, Luca

AU - Karagiannis, Sophia N.

AU - Jensen-Jarolim, Erika

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The microbiota can play important roles in the development of human immunity and the establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer medications, regulate phylogenetic variability and the quality of cross talk between innate and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and their composition have been linked to protective effects for health. Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, characterized by impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position paper, we focus on the increasing evidence defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the risk for the development of allergic and malignant diseases. We discuss novel insights into the role of microbiota in disease and patient responses to treatments in cancer and in allergy. These may highlight opportunities to improve patient outcomes with medical interventions supported through a restored microbiome.

AB - The microbiota can play important roles in the development of human immunity and the establishment of immune homeostasis. Lifestyle factors including diet, hygiene, and exposure to viruses or bacteria, and medical interventions with antibiotics or anti-ulcer medications, regulate phylogenetic variability and the quality of cross talk between innate and adaptive immune cells via mucosal and skin epithelia. More recently, microbiota and their composition have been linked to protective effects for health. Imbalance, however, has been linked to immune-related diseases such as allergy and cancer, characterized by impaired, or exaggerated immune tolerance, respectively. In this AllergoOncology position paper, we focus on the increasing evidence defining the microbiota composition as a key determinant of immunity and immune tolerance, linked to the risk for the development of allergic and malignant diseases. We discuss novel insights into the role of microbiota in disease and patient responses to treatments in cancer and in allergy. These may highlight opportunities to improve patient outcomes with medical interventions supported through a restored microbiome.

KW - allergy

KW - cancer

KW - hygiene hypothesis

KW - microbiota

KW - oncoimmunology

UR - http://www.scopus.com/inward/record.url?scp=85062791620&partnerID=8YFLogxK

U2 - 10.1111/all.13718

DO - 10.1111/all.13718

M3 - Article

C2 - 30636005

SN - 0105-4538

VL - 74

SP - 1037

EP - 1051

JO - Allergy

JF - Allergy

IS - 6

ER -

AllergoOncology: Microbiota in allergy and cancer: a European Academy for Allergy and Clinical Immunology position paper

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this